Regrettably, despite their efficacy in preclinical models, NAMPT inhibitors showed poor efficacy in clinical trials [19,20,21,22], indicating that tumor cells exploit surrogate NAD-producing routes, in particular the PH pathway, to circumvent NAMPT blockade [23,24]. Here, NAMPT is linked to neoplasm.